BETHESDA, Md., Aug. 18, 2014 /PRNewswire/ -- Pinney Associates, Inc. is pleased to welcome Bethea (Annie) Kleykamp, PhD, to our Clinical Pharmacology team. Dr. Kleykamp will be responsible for development of evidence-based literature reviews and other science-based reports on topics including clinical pharmacology, pharmaceutical risk management, abuse potential assessment and abuse deterrent drug products, Rx-to-OTC switch, and consumer health.
Dr. Kleykamp joins Pinney Associates from Hayes, Inc., where she completed over 25 systematic reviews describing the evidence-base for safety and clinical effectiveness of specific health technologies, including drugs, devices, and diagnostic procedures.
"Annie Kleykamp brings proven skills and experience in interpreting and synthesizing data into well-written evidence-based reports," said Joe Gitchell, president of Pinney Associates, a science-based health consulting firm with unique resources and broad experience in scientific, medical, public health, regulatory and commercial aspects of prescription and consumer healthcare products.
Dr. Kleykamp has extensive experience applying laboratory-based research methods to the study of psychopharmacology, cognitive psychology, smoking cessation, and aging. Dr. Kleykamp received her MA in General Psychology in 2003 from Wake Forest University and PhD in Experimental Psychology in 2007 from the Virginia Commonwealth University. She completed National Institutes of Health supported Postdoctoral Fellowships at both the Johns Hopkins University School of Medicine Behavioral Pharmacology Research Unit and at the National Institute on Drug Abuse, Nicotine Psychopharmacology Section. Her graduate and postdoctoral research focused on the effects of drugs (e.g., nicotine/tobacco, alcohol, sedative-hypnotics, opioids) on cognitive performance in healthy and drug-dependent participants. Dr. Kleykamp has also received training in the study of cognitive aging and memory training, and is particularly interested in the health-related consequences of the rapidly growing older adult population.
Pinney Associates' scientists include internationally respected leaders in the intersection of public health, behavioral science, and drugs. We help our clients to manage issues and enhance the scientific and policy environments to gain regulatory approval of, and maximize acceptance of, pharmaceutical and consumer healthcare products. Pinney Associates' experts have extensive expertise and experience in medicines with abuse potential, Rx-to-OTC Switch and consumer healthcare products.
For more information, please visit the Pinney Associates website, at www.pinneyassociates.com.
SOURCE Pinney Associates